Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
Southpoint Master Fund, LP and affiliated filers reported beneficial ownership of 10,000,000 shares of Dentsply Sirona Inc. Common Stock (CUSIP 24906P109), representing 5.0% of the class. The shares are reported as held with shared voting and shared dispositive power of 10,000,000.
The filing is a joint Schedule 13G listing Southpoint Master Fund, LP; Southpoint Capital Advisors LP; Southpoint Capital Advisors LLC; Southpoint GP, LP; Southpoint GP, LLC; and John S. Clark II as reporting persons. The ownership percentages are calculated using 199,749,333 shares outstanding as of February 20, 2026.
Scavilla Daniel T reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. reported that President and CEO Daniel T. Scavilla received a grant of 3,554.869 shares of phantom stock under a Supplemental Executive Retirement Plan. The phantom stock has an economic value equivalent to common stock at a reference price of $11.43 per share.
The award represents a SERP contribution for the year 2025 based on the 12/31/25 closing price and is held as a derivative interest. These phantom shares will be settled in common stock upon the executive’s termination of employment, and there were 3,554.869 phantom stock units reported as held directly after this grant.
Denti Aldo Mariano Roberto reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. executive Aldo Mariano Roberto Denti, EVP and Chief Commercial Officer, received an award of 829.396 shares of phantom stock under the company’s Supplemental Executive Retirement Plan for 2025, based on the 12/31/25 closing price. Each phantom share is economically equivalent to one share of common stock and becomes payable in common stock when his employment terminates. After this grant, his reported phantom stock balance is 829.396 shares.
Czerney Kevin reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. reported that VP and Chief Accounting Officer Kevin Czerney received a grant of 2,853.551 shares of phantom stock under the company’s Supplemental Executive Retirement Plan. Each phantom share is economically equivalent to one common share and becomes payable in common stock when his employment ends.
Following this award, Czerney holds a total of 6,346.9846 phantom stock shares directly, all tied to the company’s common stock and described as a SERP contribution for 2025 based on the 12/31/25 closing price.
DENTSPLY SIRONA Inc. director-related entity buys shares. A trust associated with director Gregory T. Lucier purchased 15,000 shares of common stock in an open-market transaction at a weighted average price of $12.445 per share. Following this purchase, the trust held 65,000 shares indirectly for his benefit.
Separate indirect holdings reported, with no new transactions shown, include 24,901.284 shares held by a family partnership and 21,000 shares held by a Gregory Lucier IRA.
DENTSPLY SIRONA Inc. director James D. Forbes reported an open-market purchase of common stock. On March 9, 2026, he bought 5,000 shares at $12.48 per share. After this transaction, his directly owned position increased to 10,000 common shares of the company.
DENTSPLY SIRONA Inc. executive Kevin Czerney, VP and Chief Accounting Officer, reported equity awards granted on March 4, 2026. He received stock options for 10,400 shares and a grant of 13,690 shares of common stock.
The common stock award consists entirely of restricted stock units that vest in one-third installments over three years, ending March 4, 2029. The stock options also vest in one-third annual increments through March 4, 2029 and carry an exercise price equal to 110% of the closing share price on the grant date.
Frohning Andrea L. reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. reported that SVP and CHRO Andrea L. Frohning received equity awards on March 4, 2026. She was granted stock options for 121,600 shares and an award of 26,786 restricted stock units, both vesting in equal one-third installments annually through March 4, 2029.
DENTSPLY SIRONA Inc. executive Aldo Mariano Roberto Denti, EVP and Chief Commercial Officer, reported receiving new equity awards. On March 4, 2026, he was granted stock options for 270,200 shares and 59,524 shares of common stock through restricted stock units. Both the RSUs and options vest in one-third annual installments over three years, ending March 4, 2029. The options have an exercise price set at 110% of the company’s closing common stock price on the grant date, aligning the award’s value with future share performance.
DENTSPLY SIRONA Inc. President and CEO Daniel T. Scavilla reported equity compensation awards. He received stock options covering 2,066,600 shares, which vest in annual one-third increments over three years ending March 4, 2029, with an exercise price equal to 115% of the closing price on the grant date.
He also received 145,089 shares of common stock in the form of Restricted Stock Units, vesting one-third annually over the same three-year period ending March 4, 2029. Following these awards, his directly owned common stock holdings increased to 161,839.066 shares, and he directly holds 2,066,600 stock options.